Literature DB >> 29479514

Combined Open and Endoscopic Endonasal Skull Base Resection of a Rare Endometrial Carcinoma Metastasis.

Melissa M Stamates1, John M Lee2, Ryan T Merrell3, Michael J Shinners4, Ricky H Wong5.   

Abstract

In the absence of significant extracranial disease, patients with solitary brain metastases have shown benefit with resection. Brain lesions due to endometrial cancer are uncommon, and the only described skull base involvement is limited to the pituitary gland. We report the case of a 60-year-old female with endometrial cancer who presented with weeks of right cheek pain and numbness that was accompanied by headaches. We describe the magnetic resonance imaging (MRI) findings and surgical resection of a solitary endometrial metastasis involving the infratemporal fossa, middle fossa, cavernous sinus, trigeminal nerve, and nasal sinuses. Due to extensive nasal and lateral involvement, a combined open and endoscopic approach was planned. The patient was discharged home without complication. She underwent adjuvant radiotherapy. Despite its suspected indolent course, intracranial endometrial adenocarcinoma metastases are gaining higher prevalence. This case report documents the first direct neural spread of an endometrial primary, and highlights the potential for extra-axial sites of metastasis.

Entities:  

Keywords:  anatomic pathology; endometrial carcinoma; endoscopic endonasal approach; middle fossa lesion; neuro-oncology; skull base metastasis

Year:  2018        PMID: 29479514      PMCID: PMC5823696          DOI: 10.1055/s-0038-1635098

Source DB:  PubMed          Journal:  J Neurol Surg Rep        ISSN: 2193-6358


Introduction

Endometrial cancer can rarely present with brain metastasis at initial diagnosis or at recurrence. 1 The vast majority reported are supratentorial lesions. 2 3 4 5 6 Tumors that are treated with surgery and radiotherapy show a significant survival benefit than those treated with surgery or radiotherapy alone. 1 7 8 9 10 11 Chemotherapy has not shown to significantly impact intracranial disease. 1 In the absence of significant extracranial disease, patients with solitary brain metastases have shown benefit with resection. 12 13 14 Brain lesions due to endometrial cancer are uncommon, and the only described skull base involvement is limited to the pituitary gland. 15 An extensive skull base endometrial carcinoma metastasis has not been described, and therefore, optimal treatment remains unknown. We describe the magnetic resonance imaging (MRI) findings and surgical resection of a solitary endometrial metastasis involving the infratemporal fossa, middle fossa, cavernous sinus, trigeminal nerve, and nasal sinuses.

Case Report

History and Presentation

We report the case of a 60-year-old female with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIc2 endometrial cancer who presented with weeks of right cheek pain and numbness that was accompanied by headaches. Imaging revealed a large right-sided middle fossa and infratemporal mass that involved the cavernous sinus, nasal sinuses, and tracked along the trigeminal nerve into the posterior fossae. At the time of presentation, the patient had no sign of recurrence on abdominal imaging and had excellent functional status, Eastern Cooperative Oncology Group (ECOG) 1. Her previous treatment had included a total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymphadenectomy, and omentectomy, along with pelvic radiation, vaginal cuff brachytherapy, and completion of six cycles of a carboplatin/taxol regimen 18 months prior to her presentation at our clinic.

Operation

Due to extensive nasal (turbinates, sphenoid, and maxillary sinuses) and lateral (temporalis muscle) enhancement, a combined approach was planned, with open and endoscopic stages. A right orbitozygomatic approach was performed for cavernous sinus dural elevation and anterior petrosectomy with exposure of the petrous carotid artery. This allowed for resection of the middle fossa floor, temporal dura, and access to the infratemporal fossa tumor. The anterior petrosectomy allowed complete exposure of the trigeminal nerve, from Meckel's cave to its origin at the pons. The nerve was transected at the pons ( Fig. 1 ) and tumor removal proceeded anteriorly to the posterior maxillary sinus. The next day, the patient underwent an extended endonasal approach to the infratemporal fossa. The right nasal turbinates were removed in their entirety, followed by removal of tumor in the sphenoid sinus and clival recess. The resection then proceeded laterally through the pterygoid wedge and plates and temporalis muscles. Residual tumor was left in the cavernous sinus, along the parapharyngeal carotid and internal jugular vein, and along the lateral soft palate to prevent an oral-antral fistula.
Fig. 1

Histologic specimen of trigeminal nerve stained with hematoxylin and eosin at 10× magnification. Arrow delineates normal cranial nerve, with inner foci of tumor. The immunostains on the specimen showed that it was positive for OSCAR, pankeratin, CD8/18, ER (estrogen receptors), and PR (progesterone receptors). The immunochemical and focal histological findings were similar to that seen in the previous uterine specimen.

Histologic specimen of trigeminal nerve stained with hematoxylin and eosin at 10× magnification. Arrow delineates normal cranial nerve, with inner foci of tumor. The immunostains on the specimen showed that it was positive for OSCAR, pankeratin, CD8/18, ER (estrogen receptors), and PR (progesterone receptors). The immunochemical and focal histological findings were similar to that seen in the previous uterine specimen.

Postoperative Course

The patient was discharged to home on postoperative day 3. She returned to clinic for routine wound check at 2 weeks and began intensity-modulated radiation therapy (IMRT) 1 month after surgery. Systemic chemotherapy (Tamoxifen and Megace) followed radiation. Postoperative films confirmed significant tumor debulking ( Figs. 2 and 3 ), with evidence of intended residual at the right cavernous sinus. The patient is alive and well at 12 months following surgery.
Fig. 2

Axial magnetic resonance imaging at level of right trigeminal root on presentation (left) and after resection (right).

Fig. 3

Coronal magnetic resonance imaging at root of zygoma on presentation (left) and after resection (right).

Axial magnetic resonance imaging at level of right trigeminal root on presentation (left) and after resection (right). Coronal magnetic resonance imaging at root of zygoma on presentation (left) and after resection (right).

Discussion

Intracranial disease is a rare (< 1%) complication of endometrial cancer, the most common gynecologic cancer. 16 17 18 19 The most common sites of endometrial metastases include pelvic lymph nodes, vagina, peritoneum, or lung. 20 There were 53 reports of intracranial metastases in 2007, reviewed by Orrrú et al; 3 cases reported after this date are summarized in Table 1 . Risk factors for intracranial metastasis include poorly differentiated histology, higher FIGO grade, and myometrial or lymphovascular invasion. 21 22 Our patient exhibited all of these traits.
Table 1

Endometrial intracranial disease reported in the literature after 2007

Authors and yearNo. of casesMedian age at diagnosis of IC disease (y)Location of brain lesionsMultiple brain metastasesEC disease presentTreatmentMedian survival after diagnosis of IC (mo)
Al-Mujaini et al, 2008 23 169STYesYesNSNS
Monaco et al, 2008 21 660 ** NSNSRT (6)7
Ramirez et al, 2008 24 161STYesNoRT17
Asensio et al, 2009 25 172LMNoNoRT + CHT4
Srikantia et al, 2009 26 141STYesYesRTNS
Forster et al, 2011 27 158STYesYesRT + CHT10
Cabuk-Comert et al, 2012 28 2NSIT (2)Yes = 1, No = 1Yes = 2RT (1)17.5
Gulsen and Terzi, 2013 29 171ST + ITYesNoSurgery + RT + CHT9
Nassir et al, 2014 8 174STYesNoSurgery + RT13
Gressel et al, 2015 9 2256 ** Yes = 14, No = 8Yes = 17, No = 5Surgery (1), RT (15), Surgery + RT (2), Pall (4)4.5
Kim et al, 2015 11 1958 (mean)NSYes = 8, No = 11Yes = 8, No = 11Surgery + RT (9), RT (5), Pall (2), CHT (3)23 (mean)
Sawada et al, 2016 30 140ITNoYesSurgery + RT144
Uccella et al, 2016 31 1864ST (12), IT (2), ST + IT (4)Yes = 9, No = 9Yes = 11, No = 7RT (6), RT + CHT (1), Surgery + RT (8), Pall (3)6.5
Kimyon et al, 2017 1 169 ** NoNoSurgery + RT21
Toyoshima et al, 2017 32 262LMNoNSPall1.5

Abbreviations: CHT, chemotherapy; EC, extracranial; IC, intracranial; IT, infratentorial; LM, leptomeningeal; NS, not stated; Pall, palliative care; RT, radiotherapy; ST, supratentorial.

Stated “brain metastases” or “cerebral mass” without further detail.

Abbreviations: CHT, chemotherapy; EC, extracranial; IC, intracranial; IT, infratentorial; LM, leptomeningeal; NS, not stated; Pall, palliative care; RT, radiotherapy; ST, supratentorial. Stated “brain metastases” or “cerebral mass” without further detail. With respect to treatment of intracranial endometrial disease, experience is limited to infrequent case reports, with few studies discussing more than two patients. 3 4 6 7 9 11 17 21 With these prior studies reporting survival benefit of combined therapy with surgical resection and radiation, versus surgery or radiation alone, a combined approach was planned for our skull base lesion with invasion of the trigeminal nerve. The patient's constellation of symptoms has been designated the “middle fossa syndrome” by Greenberg et al when describing clinical characteristics of skull base lesions. 33 The origin of this tumor is somewhat ambiguous due to its large size, but we suspect it centered at the pterygopalatine fossa. Although there are previous reports of intracranial endometrial metastases, this is the first reported skull base metastasis from an endometrial primary, treated with aggressive debulking via a combined open and extended endoscopic approach. An extended endonasal approach complemented our craniotomy. The craniotomy gave us access to perform complex dural repair and insert a rigid cranioplasty to separate the middle fossa and intracranial space from the nasal cavity after an extensive bony resection. 34 The endoscope provided access to tumor medial to the cavernous sinus in the sphenoid sinus, clival recess, as well as the turbinates in the nasal cavity. In preoperative discussion with the patient, planned residual was left in the cavernous sinus due to lack of significant cranial nerve palsies. Three month's MRI revealed continued decrease in residual tumor volume. In regards to skull base metastases, endoscopy has expanded access along, most notably the anterior skull base, but also the middle and posterior fossae. The benefits of using the endoscopic approach for our patient included avoiding a transfacial or transoral procedure with associated morbidity of oral-antral fistula, need for a lateral rhinotomy incision along the face and higher infection rates associated with transoral approaches. The patient was able to have her diet and activity advanced immediately after surgery, and was able to discharge once pain was well-controlled on oral analgesics. Despite its suspected indolent course and previous reference as a “neurophobic” tumor, 8 intracranial endometrial adenocarcinoma metastases are gaining higher prevalence in the U.S. population due to better survival rates. Further study should focus on multicenter pooling of data to determine the best treatment of this disease and to characterize the site of metastases. In addition to this report, there are other documented endometrial adenocarcinoma cases involving the scalp, 35 36 cranial bones, 37 and paranasal sinuses, 38 39 suggesting the incidence of distant endometrial metastases remains unknown. This case report documents the first direct neural spread of an endometrial primary, and highlights the potential for extra-axial sites of metastasis.
  37 in total

1.  Local Therapies Can Improve Intracerebral Control in Patients with Cerebral Metastasis from Gynecological Cancers.

Authors:  Liesa Dziggel; Stefan Janssen; Amira Bajrovic; Theo Veninga; Ngo Thuy Trang; Mai Trong Khoa; Steven E Schild; Dirk Rades
Journal:  Anticancer Res       Date:  2016-09       Impact factor: 2.480

Review 2.  Endometrial adenocarcinoma metastatic to the scalp: case report and literature review.

Authors:  D M Kushner; J R Lurain; T S Fu; D A Fishman
Journal:  Gynecol Oncol       Date:  1997-06       Impact factor: 5.482

Review 3.  Early brain metastases in endometrial carcinoma.

Authors:  K Kottke-Marchant; M L Estes; C Nunez
Journal:  Gynecol Oncol       Date:  1991-04       Impact factor: 5.482

Review 4.  Current concepts and controversies in the treatment of parenchymal brain metastases: improved outcomes with aggressive management.

Authors:  Gopal K Bajaj; Lawrence Kleinberg; Stephanie Terezakis
Journal:  Cancer Invest       Date:  2005       Impact factor: 2.176

Review 5.  Endometrial cancer metastasis to brain: report of two cases and a review of the literature.

Authors:  M Wroński; M Zakowski; E Arbit; W J Hoskins; J H Galicich
Journal:  Surg Neurol       Date:  1993-05

Review 6.  Endometrial clear cell carcinoma metastatic to the paranasal sinuses: a case report and review of the literature.

Authors:  Sennur Ilvan; Elif Ulker Akyildiz; Zerrin Calay; Mazhar Celikoyar; Ismet Sahinler
Journal:  Gynecol Oncol       Date:  2004-07       Impact factor: 5.482

7.  The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age.

Authors:  E M Noordijk; C J Vecht; H Haaxma-Reiche; G W Padberg; J H Voormolen; F H Hoekstra; J T Tans; N Lambooij; J A Metsaars; A R Wattendorff
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-07-01       Impact factor: 7.038

8.  Endometrial adenocarcinoma presenting as pituitary apoplexy.

Authors:  G J Lieschke; B Tress; D Chambers
Journal:  Aust N Z J Med       Date:  1990-02

9.  Intracranial and scalp metastasis of endometrial carcinoma.

Authors:  Muhammad U Farooq; Howard T Chang
Journal:  Med Sci Monit       Date:  2008-09

Review 10.  Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature.

Authors:  Gregory M Gressel; Lisbet S Lundsberg; Gary Altwerger; Tasleem Katchi; Masoud Azodi; Peter E Schwartz; Elena S Ratner; Shari Damast
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.